In the context of COVID-19 pandemic and growing tensions worldwide regarding healthcare
facilities, there is an urgent need for effective treatments likely to reduce the crunch of ICU …

Background High levels of serum interleukin-6 (IL-6) correlate with disease severity in COVID-19.
We hypothesized that tocilizumab (a recombinant humanized anti-IL-6 receptor) could …

Objectives Growing evidence suggests that vitamin D plays a key role in the pathogenesis
and progression of autoimmune diseases, including systemic lupus erythematosus (SLE). …

FIP1L1‐PDGFRA‐positive myeloid neoplasm with eosinophilia (F/P+ MN‐eo) is a rare disease:
robust epidemiological data are lacking and reported issues are scarce, of low sample‐…

Objectives The objective of this study is to better characterize the features and outcomes of
a large population of patients with mixed connective tissue disease (MCTD). Methods We …

Objective Blood concentrations of hydroxychloroquine (HCQ) vary widely among patients
with systemic lupus erythematosus (SLE). A pharmacokinetic/pharmacodynamic relationship …

Imatinib is the treatment of choice for FIP1L1/PDGFRA (F/P)-associated chronic eosinophilic
leukemia (F/P+ CEL), but its optimal dosing, duration, and possibility of discontinuation are …

Eosinophils have widespread procoagulant effects. Eosinophilic cardiovascular toxicity
mostly consists of endomyocardial damage or eosinophilic vasculitis, while reported cases of …

Background Hydroxychloroquine (HCQ) levels can be measured in both serum and whole
blood. No cut-off point for non-adherence has been established in serum nor have these …

Objective To describe the outcome and tolerance in patients treated with anti-TNFα in severe
and refractory major vessel disease in Behçet's disease (BD). Methods A multicenter study …